Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma	Digestive System Diseases, Digestive System Neoplasms, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, adenocarcinoma, carcinoma, epithelial neoplasm, hepatocellular carcinoma, liver disorder, neoplasm	Recruiting	Not stated	2025-03-25		NCT05713994

6 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Chen Xiao-ping Foundation for the Development of Science and Technology of Hubei Province	1
Chinese Cooperative Group of Liver Cancer	1
Geneplus-Beijing Co. Ltd.	10
Haplox Biotechnology Co., Ltd.	1
The Second Affiliated Hospital of Fujian Medical University	9
Ze-yang Ding, MD	1

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
The Second Affiliated Hospital of Fujian Medical University	Quanzhou	China	7
TongjiHospital	Wuhan	China	1